Feng Mingque, Cheng Jia, Su Yalan, Tong Jingdi, Wen Xiangfu, Jin Tianxiong, Ren Meiyi, Song Deyuan, Song Jinshang, Li Xiaohan, Xie Qinna, Liu Mingchao
College of Veterinary Medicine, Hebei Agricultural University, Baoding 071000, China.
College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
Int J Mol Sci. 2024 Dec 20;25(24):13660. doi: 10.3390/ijms252413660.
() is a common pathogen that causes diarrhea in newborns and animals. Antibiotics are typically used to treat bacterial diarrhea, a global intestinal health issue. Probiotics have gained interest as a potential substitute for antibiotics in the management of -induced diarrhea and present novel therapeutic options. In this study, the probiotic properties of SNF7 ( SNF7) isolated from feces were investigated, and whole genome sequencing was performed to evaluate the properties of the strain. Furthermore, we investigated the protective effects of SNF7 in a mouse model of K99 infection. SNF7 exhibits a high survival rate in artificial gastroenteric fluid and bile salt environments, along with an antagonistic effect against O:K (B), (), and K99. Multiple genes with probiotic properties, including bacteriostasis, anti-inflammation, antioxidant, CAZyme, and the utilization of carbohydrate compounds, were identified in genome. SNF7 prevented the gut barrier from being damaged by K99, reducing the clinical manifestations of the infection. Furthermore, SNF7 reduced the expression of inflammatory cytokines (IL-6, IL-1β, and TNF-α) by inhibiting the phosphorylation of proteins linked to the NF-κB and MAPK signaling pathways. SNF7 improved the intestinal microbial barrier, controlled the balance of the intestinal microecology, and reduced the entry of harmful microbes into the intestine. By controlling gut flora and reducing the inflammatory response, SNF7 may be able to prevent and treat K99 infections. The application of SNF7 in the creation of probiotic formulations to stop intestinal illnesses brought on by infections is clarified by this work.
()是一种导致新生儿和动物腹泻的常见病原体。抗生素通常用于治疗细菌性腹泻,这是一个全球性的肠道健康问题。益生菌作为抗生素在治疗 - 诱导腹泻方面的潜在替代品受到关注,并提供了新的治疗选择。在本研究中,对从粪便中分离出的SNF7(SNF7)的益生菌特性进行了研究,并进行了全基因组测序以评估该菌株的特性。此外,我们在K99感染的小鼠模型中研究了SNF7的保护作用。SNF7在人工胃肠液和胆盐环境中表现出较高的存活率,同时对O:K(B)、()和K99具有拮抗作用。在基因组中鉴定出多个具有益生菌特性的基因,包括抑菌、抗炎、抗氧化、CAZyme以及碳水化合物化合物的利用。SNF7可防止肠道屏障被K99破坏,减少感染的临床表现。此外,SNF7通过抑制与NF-κB和MAPK信号通路相关的蛋白质磷酸化来降低炎性细胞因子(IL-6、IL-1β和TNF-α)的表达。SNF7改善了肠道微生物屏障,控制了肠道微生态平衡,减少了有害微生物进入肠道。通过控制肠道菌群和减少炎症反应,SNF7可能能够预防和治疗K99感染。这项工作阐明了SNF7在创建益生菌制剂以阻止由感染引起的肠道疾病方面的应用。